Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study.

Tetsuya ShindoKo KobayashiToshiaki TanakaNaoya Masumori

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018)

Levocarnitine supplementation for cancer-related fatigue in patients treated with sunitinib appears to have a potential benefit. However, further study with a larger number of patients and longer follow-up is crucial to confirm this.

Keyphrases

renal cell carcinoma
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
metastatic renal cell carcinoma
risk assessment
physical activity
climate change
smoking cessation